Thermo Fisher Scientific Announces 4th Annual Cellome Award Winner
News Feb 26, 2014
Thermo Fisher Scientific, this week will present its 2014 Cellome Award to the authors of the peer-reviewed article, “A regenerative approach to the treatment of multiple sclerosis,” that was featured in the October 2013 issue of Nature.
Vishal Deshmukh, of The Scripps Research Institute will be accepting the award on behalf of all the contributing authors of the paper during the Cambridge Healthtech Institute’s High Content Analysis Meeting, February 19-20, 2014 in La Jolla, CA.
Contributing to the paper’s selection was the use of high content technology and its potential clinical impact by showing the effectiveness of benztropine administration alone or in conjunctive therapy in a Multiple Sclerosis model to enhance remyelination and functional recovery.
The Thermo Scientific Cellome Award is presented annually by Thermo Fisher Scientific’s cellular imaging and analysis business to the authors of the most impactful peer-reviewed article which showcases high content technology as a fundamental method.
Papers using Thermo Scientific cellular imaging and analysis products are collected and reviewed throughout the year, and one paper is selected which represents the best use of high content technology in life science research.
“We congratulate Vishal and his team on receiving this year’s award,” said Audra Ziegenfuss, technical product manager, cellular imaging and analysis, Thermo Fisher. “This in vivo evidence contributes to the development of novel therapies in the treatment of multiple sclerosis and ultimately improved clinical management of this patient population.”
“I have taken a phenotypic rather than target based approach using various readouts, including high-throughput high content imaging,” said Deshmukh. “I am extremely happy to receive this award as recognition of our HCI-HTS efforts and hope to continue using this approach in various other assays."
Contributors to the Nature paper include: Vishal A. Deshmukh, Virginie Tardif, Costas A. Lyssiotis, Chelsea C. Green, Bilal Kerman, Hyung Joon Kim, Krishnan Padmanabhan, Jonathan G. Swoboda, Insha Ahmad, Toru Kondo, Fred H. Gage, Argyrios N. Theofilopoulos, Brian R. Lawson, Peter G. Schultz, and Luke L. Lairson.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018